Skip to main content

Advertisement

Table 1 Demographics of included studies

From: Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression

Study, Year Study design/setting VKA-treated N Mean age VKA experience, % Geographic region Interpolation method Self -management Duration of therapy, months (Patient-years) VKA studied
Abdelhafiz 2004 [11] PD/AC clinic 402 72 0% Europe Linear N 19 (637) W
Abdelhafiz (<75) 2008 [12] PD/AC clinic 203 64 0% Europe Linear N 19 (321) W
Abdelhafiz (≥75) 2008 [12] 199 80 19 (315)
Akdeniz 2005 [13] PD/Community 208 66 NR Turkey - - - W
Albers 2005 [14] RCT 1962 72 85% N. America Linear N 20 (3270) W
Anderson 2004 [15] RD/AC clinic 87 NR 100% N. America NR N 12 (87) W
Ansell (Italy) 2007 [16] RD/AC clinic 177 72 100% Multinational Linear N 12 (177) W
Ansell (Spain) 2007 [16] RD/AC clinic 218 72 12 (218) A
Ansell (US) 2007 [16] RD/Community 686 75 12 (686) W
Ansell (Canada) 2007 [16] RD/Community 152 74 12 (152) W
Ansell (France) 2007 [16] RD/Community 278 73 12 (278) F
Aronow 1999 [17] PD/Community 125 83 NR N. America NR N 34 (354) W
Boulanger 2006 [18] RD/Community 6454 68 65% N. America Linear N 12 (6454) W
Burton (<75) 2006 [19] RD/Community 260 NR Mixed Europe Linear N 25 (539) W
Burton (>75) 2006 [19] 341 15 (414)
Cafolla (Manual) 2011 [20] RD/Community 576 NR 100% Europe Linear N 8 (384) A,W
Cafolla 2012 [21] PD/AC clinic 57 85 100% Europe Linear N 18 (86) W
Cheung 2005 [22] RD/Community 555 70 100% Asia - N 19 (893) W
Chung 2011 [23] RCT 75 65 55% Asia Linear N 3 (19) W
Connolly 1991 [24] RCT 187 68 0% N. America Linear N 15 (234) W
Connolly 2006 [25] RCT 3371 70 78% N. America Other N 15 (4214) NR
Copland 2001 [26] RD/AC Clinic 328 70 100% UK - N 21 (458) W
Currie (stable) 2005 [27] RD/Community 787 74 100% Europe Linear N 35 (2282) W
Currie (unstable) 2005 [27] 726 78 35 (2105)
Dentali 2012 [28] PD/AC Clinic 221 75 100 Europe - N 3 (663) W
DiMarco 2005 [29] RCT NR 70 NR N. America - N 42 (−) W
Dimberg (control SP) 2012 [30] RD/Community 84 69 100% Europe Linear N 12(84) W
Dimberg (control ACC) 2012 [30] RD/AC clinic 271 72 12(271)
EAFT 1995 [31] RCT 214 71 0% Europe - N 24 (377) W,A,F
Ellis 2009 [32] RCT 66 68 97% N. America Linear N 3 (17) T
Evans 2000 [33] PD/AC clinic 288 76 0% Europe NR N 24 (576) W
Evans 2001 [34] PD/AC clinic 214 78 NR Europe NR N 24 (448) W
Ezekowitz 2007 [35] RCT 70 69 100% Multinational NR N 3 (18) W
Fang 2004 [36] RD/AC Clinic 170 78 100 N. America - N - W
Gallagher 2011 [37] RD/Community 18113 73 72% Europe Linear N 20 (30188) W
Garcia (naïve) 2013 [38] RCT 3888 70 0% Multinational Linear N 22 (7128) W
Garcia (exp) 2013 [38] 5193 70 100% 22 (9521)
Gladstone 2009 [39] RD/Community 423 78 100 N. America - N - W
Go 2003 [40] RD/AC clinic 7445 71 Mixed N. America Linear N 21 (12958) W
Gullov 1998 [41] RCT 170 73 0% Europe Linear N 25 (355) W
Gullov 1999 [42] RCT 170 73 0 Europe Linear N 25 (355) W
Gurwitz 1997 [43] RD/Community 117 83 32% N. America Linear N 12 (117) W
Hannon 2011 [44] PD/Community 43 77 100 Europe - N - W
Hart 2011 [45] RCT 523 NR 0 N. America - N 13 (575) W
Heidinger 2000 [46] RD/Community 753 62 100% Europe NR Y 12 (769) NR
Hellemons 1999 [47] RCT 131 70 0 Europe - N 32 (354) P,A
Ho (hypertension) 2011 [48] RD/Community 278 70 NR Multinational Linear N 48 (1112) W
Ho (no HTN) 2011 [48] 198 69 48 (792)
Holmes 2009 [49] RCT 244 73 100% Multinational NR N 18 (366) W
Hori 2012 [50] RCT 250 71 90% Asia Linear N 30 (625) W
Hylek 2003 [51] RD/Community 188 76 100 N. America - N - W
Hylek 2007 [52] PD/AC clinic 472 77 0% N. America Linear N 12 (360) W
Jacobs 2009 [53] RD/Community 90 NR 85% N. America Linear N 12 (90) W
Jones 2005 [54] RD/Community 2223 72 100% Europe Linear N 31 (5743) W
Kalra 2000 [55] PD/AC clinic 167 77 0% Europe Linear N 24 (296) W
Kim 2009 [56] RD/AC clinic 129 64 100% Asia Other N 24 (258) W
Kim 2010 [57] PD/AC clinic 499 73 100% N. America Linear N 5 (208) W
Kulo (warfarin) 2009 [58] PD/Community 60 66 100% Europe NR N 12 (60) W
Kulo (acenocoumarol) 2009 [58] 57 68 12 (57) A
Lee 2012 [59] RD/Community 200 67 NR Asia Linear N 42 (700) W
Malik 2000 [60] RD/AC clinic 247 68 100% N. America Other N 13 (268) W
Mant 2007 [61] RCT 488 82 40% Europe Linear N 32 (1301) W
Matchar (control) 2002 [62] RCT 317 76 NR N. America Linear N 9 (238) W
Matchar (prior to ACC) 2002 [62] PD/AC clinic 363 75 9 (272)
McBride 2007 [63] PD/Community 361 71 90% Europe Linear N 9 (271) W
McCormick 2001 [64] RD/Community 174 87 100% N. America Linear N 12 (174) W
Melamed 2011 [65] RD/Community 906 72 100% Israel Linear N 10 (769) W
Menzin 2005 [66] RD/AC clinic 600 72 63% N. America Linear N 11 (525) W
Morocutti 1997 [67] RCT 454 72 NR Europe - N 12 W
Neree 2006 [68] RD/Community 395 74 100% Europe Linear N 4 (132) P,A,W
Nichol (ACC) 2008 [69] RD/AC clinic 351 NR 100% N. America Linear N 31 (920) W
Nichol (UC) 2008 [69] RD/Community 756 18 (1165)
Njaastad 2006 [70] RD/AC clinic 421 NR 0% Europe Linear N 14 (475) W
Nozawa 2001 [71] PD/Community 156 68 100 Asia - N 22 (286) W
Ogawa 2011 [72] RCT 75 72 0 Asia Linear N 3 (210) W
Okumura (<70) 2011 [73] PD/Community 208 NR 100% Asia Linear N 23 (399) W
Olsson 2003 [74] RCT 1703 70 73% Multinational NR N 16 (2271) W
Ono 2005 [75] PD/Community 63 76 0 Asia Linear N 28 (145) W
Patel 2011 [76] RCT 7133 73 63% Multinational Linear N 20 (11888) W
Pengo 1998 [77] RCT 153 74 0% Europe Linear N 14 (179) W
Pengo 2001 [78] PD/AC Clinic 433 68 0 Europe Linear N 17 (615) W,A
Pengo 2010 [79] RCT 132 79 0% Multinational Linear N 64 (704) W
Perez-Gomez 2004 [80] RCT 237 70 0% Europe NR N 33 (556) A
Poli 2007 [81] PD/AC clinic 290 82 100% Europe Linear N 34 (814) NR
Poli 2009 [82] PD/AC Clinic 783 75 0% Europe Linear N 39 (2567) W
Poli 2009 [83] PD/AC clinic 578 75 100% Europe Linear N 38 (1854) NR
Poli 2009 [84] PD/AC clinic 780 75 100 Europe Linear N 36 (2406) W
Poller (Manual) 2008 [85] RCT 2967 67 0% Multinational Linear N 17 (4203) W, A, P
Sadanaga 2010 [86] PD/Community 259 74 100 Asia - N 25 (544) W
Samsa (ACC) 2000 [87] RD/AC Clinic 43 69 NR N. America Linear N 9 (32) W
Samsa (Rochester) 2000 [87] RD/Community 61 9 (46)
Samsa (R. Triangle) 2000 [87] RD/Community 125 9 (94)
Schwammenthal 2010 [88] PD/Community 111 76 100 Israel - N - W
Sconce (vitamin K) 2007 [89] RCT 35 75 100% Europe Linear N 6 (18) W
Sconce (placebo) 2007 [89] 35 74
Shen 2007 [90] RD/Community NR 72 55% N. America NR N 40 (24179) W
Singer 2009 [91] RD/Community 9217 77 100 N. America - N 72 (33497) W
SPAF III 1996 [92] RCT 523 71 56% N. America NR N 13 (567) W
Sullivan (women) 2012 [93] RCT 1594 71 87% Multinational Linear N 42 (5579) W
Sullivan (men) 2012 [93] 2466 68 86% 42 (8631)
Tincani 2009 [94] PD/AC Clinic 90 92 100% Europe Linear N 12 (90) W
Van Spall 2012 [95] RCT 6022 72 47% Multinational Linear N 24 (12044) W
Voller (self-mgmt) 2005 [96] RCT 101 65 0% Europe NR Y 8 (68) NR
Voller (UC) 2005 [96] 101 64 N
Walker (MHC) 2011 [97] RD/AC Clinic 22 NR 100% N. America Linear N 12 (22) W
Walker (no MHC) 2011 [97] 62 12 (62)
Wieloch (AF) 2011 [98] RD/Community 11770 73 100% Europe Linear N 12 (11770) W
Weitz 2010 [99] RCT 250 66 35% N. America Linear N 3 (63) W
Wyse 2002 [100] RCT NR 70 NR N. America - N 42 W
Yamaguchi 2000 [101] RCT 55 66 NR Asia - N 22 (101) W
Yasaka 2001 [102] PD/Community 88   100 Asia - N 22 (161) W
Yousef 2004 [103] RD/Community 739 73 100% Europe NR N 24 (1484) W
  1. VKA = vitamin K antagonist; RCT = randomized controlled trial; RD = retrospective design; PD = prospective design; AC clinic = anticoagulation clinic; AF = atrial fibrillation; NR = not reported; N = North; VKA = Vitamin K Antagonist; W = warfarin; A = acenocoumarol; T = tecarfarin; P = phenprocoumon; F = fenprocoumon.